OCAT News Alert Ocata Therapeutics Inc. (OCAT) 6.3600 02/15/2015

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ocata Therapeutics Inc. (OCAT) 6.3600 $OCAT

NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST

VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)

Ocata terminates equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 6:07AM CST


Ocata Therapeutics Withdraws Offering of Common Stock
Business Wire - Wed Feb 11, 3:44PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has withdrawn its previously announced public offering of 10,000,000 shares of common stock under its shelf registration statement given current market conditions.

Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 04, 8:12AM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 17th Annual BIO CEO and Investor Conference on Monday, February 9, 2015 at 9:30 a.m. ET in New York City.

Ocata Therapeutics names John Heffernan as VP of Manufacturing
M2 - Wed Feb 04, 5:24AM CST
Ophthalmology company Ocata Therapeutics (OTCBB:OCAT) revealed on Tuesday the addition of John Heffernan as vice president of its Manufacturing.

Ocata Therapeutics Appoints John Heffernan, Vice President of Manufacturing
Business Wire - Tue Feb 03, 3:10PM CST
Ocata Therapeutics, Inc. ("Ocata"; OTCBB: OCAT), a leader in the field of regenerative ophthalmology, today announced the appointment of John Heffernan, a pharmaceutical industry veteran, to the newly created position of Vice President of Manufacturing. Mr. Heffernan has a breadth of experience in all facets of manufacturing in the cell therapy space.

Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure
M2 - Tue Feb 03, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb556t/regenerative) has announced the addition of the "Regenerative Medicine and Stem cell based Cell therapies-Drugs of the Future Offering Hope for Cure" report to their offering. Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets, approaches and biology are discovered. Improved health care, nutrition and preventive medicine in the last few decades have all helped in increasing life expectancy WW. However, this has not translated in any reduction in the incidences or prevalence of chronic or critical illnesses! On the contrary, the incidence of chronic diseases like diabetes, obesity, arthritis etc. as well as cancer and the maladies associated with aging (dementia, Alzheimer's etc.) are on the rise. Consequently the pharma industry continues to grow and is projected to achieve sales in excess of the trillion dollar mark by 2020. By the next decade, one field which is poised to bring a paradigm change in the way diseases are treated is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic has reached a critical mass, warranting a close watch by those interested in keeping pace with the development of new medicines. This report describes the key growth drivers and reasons for why this sector is poised for the "golden dawn" and forecasts that in the coming years, the translation of stem cell research to the clinic and market and Stem Cell Technologies Will Begin to Break Through by 2017. Key Topics Covered: 1. Executive summary 2. Introduction 3. Tough Choice- Autologous vs. Allogenic " Therapies 4. Regulatory Scenario 5. Marketed Cell based/Stem Cell Products 6. Progress and Challenges 7. Merger and Acquisition- Gaining Momentum in Regenerative Space 8. Progress in Specific Therapy Areas Companies Mentioned - CESCA Therapeutics Inc. [KOOL] - JCR Pharmaceuticals [4552:JP] - Japan Tissue Engineering Co., Ltd [7774:JP] - Medipost Co. Ltd [078160:KS] - Mesoblast Ltd [MSB:AU] - OCATA Therapeutics Inc. [OCAT] - Orgenesis [ORGS] - Pluristem Therapeutics Inc [PSTI:IT] - TiGenix NV [ TIG:BB] For more information visit http://www.researchandmarkets.com/research/lb...generative
KOOL: 0.88 (-0.14), PSTI: 2.91 (+0.01)

Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)

Vericel Corporation Names Three New Board Members
Marketwired - Wed Jan 07, 7:45AM CST
Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the appointment of three new members to the company's board of directors: Steven C. Gilman, Ph.D., executive vice president and chief scientific officer of Cubist Pharmaceuticals; Kevin F. McLaughlin, senior vice president and chief financial officer of Acceleron Pharma; and Paul Wotton, Ph.D., president and chief executive officer of Ocata Therapeutics.
CBSTZ: 0.06 (unch), VCEL: 3.71 (-0.01), XLRN: 38.02 (+0.07)

The Butterfly Effect: Advanced Cell Technology Becomes Ocata Therapeutics (OCAT)
Scrying Biotech - at Seeking Alpha - Mon Dec 08, 8:58AM CST


Ocata Therapeutics Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Dec 02, 3:10PM CST
Ocata Therapeutics, Inc. (OTCBB: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced its intention to offer and sell 10,000,000 shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. As part of this offering, Ocata Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock.

Ocata Therapeutics to Present at 26th Annual Piper Jaffray Health Care Conference
Business Wire - Tue Nov 25, 8:19AM CST
Ocata Therapeutics, Inc., (OTCBB: OCAT) today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Health Care Conference on Tuesday, December 2, 2014 at 9:30 a.m. EST in New York City.

Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation from the European Medicines Agency
Business Wire - Mon Nov 24, 8:22AM CST
Ocata Therapeutics, Inc., (OTCBB:OCAT) today announced that it has been granted Advanced Therapy Medicinal Product (ATMP) designation for its RPE therapy for macular degeneration. This designation is an essential step in allowing companies to commercialize products effectively across the European Union.

A Timely Interview With BioTime's CEO And His Chief Commercial Officer
JMY Investments - at Seeking Alpha - Mon Nov 17, 10:39AM CST

BTX: 4.07 (+0.05), STEM: 1.09 (-0.01)

Advanced Cell Technology Changes Name to Ocata Therapeutics
Business Wire - Fri Nov 14, 8:02AM CST
Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's shareholders, reflects the Company's focus on the development of regenerative cell therapeutics for the treatment of ophthalmic diseases. "Ocata" is a Native American name for "healer," a term associated with repair and regeneration as opposed to merely slowing the progression of disease, or treatment of symptoms.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teledyne LeCroy Drives AI Scale-up with New UALink

Updated Category News Views 0

Pushing the Boundaries of AI Infrastructure Teledyne LeCroy is shaking things up with their latest innovation—the Xena Z2244 Ultra Accelerator Link™ Traffic Generator, a tool that promises to turbocharge validation systems for AI and HPC scale-up infrastructure. If you're dealing with the nuts and bolts of next-gen networks, this one's worth your attention. Setting a...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 78

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 25

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 85

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 59

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 102

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading